—
C+
C+ The full Closelook — membership. Open the C+ overview

Corcept Therapeutics Incorporated (CORT) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Corcept Therapeutics Incorporated

CORT in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Corcept develops drugs that block cortisol receptors, treating disorders where the body produces too much of the hormone. Its approved medicine, Korlym, treats hyperglycaemia linked to Cushing's syndrome, and it is testing further cortisol modulators, including relacorilant and miricorilant, for other endocrine and neurologic conditions. It was incorporated in 1998 and is based in Redwood City, California.
Where it sits in the stack
Corcept carries no seat in our index and sits outside the AI-linked sleeves the diary tracks; it belongs to the Healthcare sector of our wider universe, grouped by country with other US-listed biopharmaceutical names.
Who it is priced against
The diary's peer group is drawn from scored Healthcare names in the US, including argenx, Regeneron, Vertex Pharmaceuticals and BeiGene, plus device and services names such as Globus Medical and IDEXX Laboratories.
Why Closelook tracks it
Corcept holds no index seat but carries a Closelook score, with momentum the strongest module and valuation the weakest; the diary noted it once in a Midday 10 piece listing health-care names making fresh 52-week highs.
What the diary watches
Whether trial readouts on relacorilant or miricorilant shift the valuation module, which currently lags the rest of the scorecard.

Corcept Therapeutics Incorporated (CORT) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 56/100 composite (momentum 93, quality 46, valuation 23) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for CORT, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Healthcare · US · 8 names with week and year-to-date

Peer group

Healthcare · US

Scored names in the same sector and country from the Closelook universe.

Compared against CORT on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sector × region Health care in US: +0.7% week · +0.4% month · +10.2% quarter · +6.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-16
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Corcept Therapeutics Incorporated (CORT)?

Corcept Therapeutics Incorporated trades as CORT on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-18.

Is CORT in a Closelook index?

Not currently — Corcept Therapeutics Incorporated is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

What is Corcept Therapeutics Incorporated's Closelook composite score?

56 out of 100, with momentum 93, quality 46 and valuation 23 sub-scores, as of 2026-09-18. Scores are Closelook's own research readings, not ratings or investment advice.

Where does CORT trade against its moving averages?

Uptrend stack intact: Trades +6.5% vs the 50-day and +68.3% vs the 200-day average, 9.1% below the 52-week high and +300.8% off the 52-week low; a golden cross printed 61 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Corcept Therapeutics Incorporated do?

Corcept develops drugs that block cortisol receptors, treating disorders where the body produces too much of the hormone. Its approved medicine, Korlym, treats hyperglycaemia linked to Cushing's syndrome, and it is testing further cortisol modulators, including relacorilant and miricorilant, for other endocrine and neurologic conditions. It was incorporated in 1998 and is based in Redwood City, California. The diary's peer group is drawn from scored Healthcare names in the US, including argenx, Regeneron, Vertex Pharmaceuticals and BeiGene, plus device and services names such as Globus Medical and IDEXX Laboratories.

Where does Corcept Therapeutics Incorporated sit in the AI build-out?

Corcept carries no seat in our index and sits outside the AI-linked sleeves the diary tracks; it belongs to the Healthcare sector of our wider universe, grouped by country with other US-listed biopharmaceutical names. Corcept holds no index seat but carries a Closelook score, with momentum the strongest module and valuation the weakest; the diary noted it once in a Midday 10 piece listing health-care names making fresh 52-week highs.

Where has Closelook written about Corcept Therapeutics Incorporated?

Corcept Therapeutics Incorporated appears in 1 Closelook piece, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelook said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for CORT, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelook

Where CORT appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Related in the Closelook universe